Cerevel Therapeutics Announces Proposed Public Offering of Common Stock
August 10, 2022 16:01 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics Holdings, Inc. (“Cerevel”, “we”, “us” or “our”) (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain...
Cerevel Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
August 01, 2022 06:15 ET
|
Cerevel Therapeutics
Initiated two parallel, adequately-powered Phase 2 trials of emraclidine in schizophrenia with data expected 1H 2024 Phase 1 trial of emraclidine to be initiated by year-end to support future...
Cerevel Therapeutics to Report Second Quarter 2022 Financial Results and Pipeline Update on Monday, August 1, 2022
July 25, 2022 17:00 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., July 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Updates to its Board of Directors
June 15, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., June 15, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced today...
Cerevel Therapeutics to Present at the Jefferies Healthcare Conference
May 25, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., May 25, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
May 10, 2022 06:30 ET
|
Cerevel Therapeutics
On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by mid-year 2022 Data for the darigabat Phase 2 proof-of-concept trial in focal epilepsy now...
Cerevel Therapeutics to Report First Quarter 2022 Financial Results and Pipeline Update on Tuesday, May 10, 2022
April 13, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., April 13, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...
Cerevel Therapeutics Announces Upcoming Presentations at AAN 2022
March 31, 2022 06:30 ET
|
Cerevel Therapeutics
Oral presentation to highlight preclinical data demonstrating robust antiepileptic activity for darigabat in drug-resistant focal epilepsy Poster presentations to include further evidence of...
Cerevel Therapeutics to Present at the Stifel 4th Annual CNS Day Event
March 21, 2022 06:30 ET
|
Cerevel Therapeutics
CAMBRIDGE, Mass., March 21, 2022 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that...
Cerevel Therapeutics Provides Update on Pipeline Progress along with Fourth Quarter and Full Year 2021 Financial Results
March 01, 2022 06:30 ET
|
Cerevel Therapeutics
Announced positive results from Phase 1 healthy volunteer trial of darigabat in acute anxiety On track to initiate two parallel adequately-powered Phase 2 trials of emraclidine in schizophrenia by...